A Model of a modern service company

Praca składa się z sześciu rozdziałów. W pierwszym rozdziale przedstawiono historię przedsiębiorstwa w gospodarce europejskiej oraz dokonano omówienia specyfiki funkcjonowania współczesnego przedsiębiorstwa usługowego. W drugim rozdziale omówiono teorie przedsiębiorstw. Trzeci rozdział został poświęcony sektorowi usług w polskiej gospodarce. W czwartym rozdziale opracowano model współczesnego przedsiębiorstwa usługowego. Następnie na podstawie danych empirycznych przedstawiono prawidłowości zachodzące w przedsiębiorstwach usługowych z województwa podlaskiego. W piątym rozdziale przeprowadzono symulację modelową w oparciu o program AMOS. W szóstym rozdziale przedstawiono zbiór wniosków i rekomendacji oraz określono obszary dalszych badań nad przedsiębiorstwem usługowym.The work consists of six chapters. In the first chapter we present the history of the company in the European economy and discusses the specifics of the functioning of a modern service company. The second chapter discusses theories of enterprises. The third chapter is devoted to the services sector in the Polish economy. In the fourth chapter a model of modern service company. Then, based on empirical data presented regularities in service enterprises of Podlaskie. In the fifth chapter, the simulation model based on the AMOS program. In the sixth chapter presents a set of conclusions and recommendations and identified areas for further research service company.Wydział Ekonomii i Zarządzania. Katedra Ekonomii Politycznej

New Biosensor for Determination of Neuropilin-1 with Detection by Surface Plasmon Resonance Imaging

Neuropilin-1 is transmembrane protein with soluble isoforms. It plays a pivotal role in both physiological and pathological processes. NRP-1 is involved in the immune response, formation of neuronal circuits, angiogenesis, survival and migration of cells. The specific SPRI biosensor for the determination of neuropilin-1 was constructed using mouse monoclonal antibody that captures unbound NRP-1 form body fluids. The biosensor exhibits linearity of the analytical signal between 0.01 and 2.5 ng/mL, average precision value 4.7% and recovery between 97% and 104%. The detection limit is 0.011 ng/mL, and the limit of quantification is 0.038 ng/mL. The biosensor was validated by parallel determination of NRP-1 in serum and saliva samples using the ELISA test, with good agreement of the results

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from

Aim of the study: To assess resource utilization and costs of treatment with lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland. Material and methods: A multicentre, non-interventional, observational study on resource utilization in Polish acromegalic patients treated with ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study recruited adult acromegalic patients treated medically for ≥ 1 year including at least 3 injections of ATG120. Data on dosing interval, aspects of administration, and resource utilization were collected prospectively during 12 months. Costs were calculated in PLN from the public health-care payer perspective for the year 2013. Results: 139 patients were included in the analysis. Changes in dosing regimen were reported in 14 (9.4%) patients. Combined treatment was used in 11 (8%) patients. Seventy patients (50%) received ATG120 at an extended dosing interval; the mean number of days between injections was 35.56 (SD 8.4). ATG120 was predominantly administered in an out-patient setting (77%), by health-care professionals (94%). Mean time needed for preparation and administration was 4.33 and 1.58 min, respectively, mean product wastage - 0.13 mg. Patients were predominantly treated in an out-patient setting with 7.06 physician visits/patient/ year. The most common control examinations were magnetic resonance imaging of brain and brain stem (1.36/ patient/year), ultrasound of the neck (1.35/patient/year), GH (1.69/pa tient/ year), glycaemia (1.12/patient/year), IGF-1 (0.84/patient/year), pituitary-thyroid axis hormone levels assessment (TSH-0.58/patient/year, T4-0.78/patient/ year). There were 0.43 hospitalizations/ patient/year. For direct medical costs estimated at PLN 50 692/pa tient/ year the main item was the costs of ATG120 (PLN 4103.87/patient/month; 97%). The mean medical cost, excluding pharmacotherapy, was PLN 1445/patient/year (out-patient care - 49%, hospitalization - 23%, diagnostics/laboratory tests - 28%). Conclusions: These results represent the current use of ATG120 in the population of Polish acromegalic patients in a realistic clinical setting. Findings that 50% of patients could be treated with dose intervals of longer than 28 days support the potential of ATG120 to reduce the treatment burden